Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia

Author： Mintz Matthew L.   Minervini Gianmaria  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.30, Iss.5, 2014-05, pp. : 761-770

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 581-590

John Wiley & Sons Inc

Access to resources Recommend Favorite

The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus

By  

DIABETIC MEDICINE, Vol. 32, Iss. 7, 2015-07 ,pp. : 890-898

John Wiley & Sons Inc

Access to resources Recommend Favorite

Empagliflozin as add‐on to metformin in people with Type 2 diabetes

By  

DIABETIC MEDICINE, Vol. 32, Iss. 12, 2015-12 ,pp. : 1555-1567

John Wiley & Sons Inc

Access to resources Recommend Favorite

Two dose‐ranging studies with PF‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 751-759

John Wiley & Sons Inc

Access to resources Recommend Favorite

Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin

By Stenlöf Kaj   Raz Itamar   Neutel Joel   Ravichandran Shoba   Berglind Niklas   Chen Roland  

Current Medical Research and Opinion, Vol. 26, Iss. 10, 2010-10 ,pp. : 2355-2363

Informa Healthcare

Access to resources Recommend Favorite